The DCAT Pulse: The Tariff Outlook & Pharma

Evolving US tariff policy is a key variable in the cost structures, manufacturing strategies, and supply chains of bio/pharma companies and their suppliers. A DCAT webinar gives an executive briefing on what is crucial to consider in supply planning amid tariff uncertainty.

Evolving US tariff/trade policy is top of mind for the bio/pharma industry and is a key variable in the cost structures, manufacturing strategies, and supply chains of bio/pharmaceutical companies and their suppliers. Unpacking what tariffs are in place, and what additional tariffs may come to be and how they will be implemented is a challenge unto itself, but an even greater challenge is how can companies put forth effective supply plans amid such tariff uncertainty?

To address that critical question, a DCAT webinar, The Tariff Outlook & Pharma, airing January 22, 2026 (10:00-10:30 AM EST-US), brings together leading industry experts on what may lie ahead in 2026 and what is important to consider in effective supply planning. Jens Charlieson, Head of Transport & Trade Compliance at Swedish Orphan Biovitrum AB (Sobi), and Gabriela de Almeida, Managing Director and Partner at Boston Consulting Group, will share key insights on the crucial factors and scenarios to consider for effective supply planning and trade compliance.

The webinar is part of The DCAT Pulse, a new, member-focused insights hub from the Drug, Chemical & Associated Technologies Association (DCAT) that brings together fresh perspectives and seasoned expertise, spotlighting trends and opportunities that help DCAT Member Companies stay informed, engaged, and ahead of the curve in a dynamic marketplace.

The webinar, The Tariff Outlook & Pharma, was developed by the volunteer DCAT Supply Management Committee, composed of senior to mid-level executives involved in sourcing, procurement and supply management. The webinar is provided exclusively and complimentary to all employees of DCAT Member Companies, who can register here. Not able to attend the webinar on January 22? No problem. The webinar will be available for on-demand viewing, but you must register to view.

Recent Feature Articles

CDMO Moves: Lonza Increasing Position in US

By
Lonza is increasing its position in the US with a pending acquisition of five CDMO sites from the life-sciences business of Merck KGaA. What sites and capabilities is the company gaining in the deal?

Orphan Drugs: The Top Products & Companies

By
Orphan drug sales are projected to reach a peak of 30% of the global prescription drug market by 2027 and sales of $400 billion by 2032. What products and companies are leading growth?

Anthropic & Pharma: What Comes Next

By
In what is projected to be one of the largest IPOs in history, the AI giant, Anthropic, has taken the first step in holding an IPO, with AI in bio/pharmaceutical development a key component in its growth strategy.

Indian Pharma Companies & Innovator Drugs

By
Sun Pharma’s pending $11.75-billion acquisition of Organon was one of the largest M&A in 2026 and is aligned with its strategy of in part diversifying into innovator drugs, a step taken by other Indian companies.